newsfilter
← Latest News
GlobeNewswire·

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights

Enrollment complete for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease Anticipate topline results in late 2026 Topline results from the Phase 1 study